From GlobeNewswire: 2025-03-25 06:01:00

Phase 3 4WARD trial in chronic neutropenia is now activated at ~90% of targeted sites; full enrollment expected in 3Q or 4Q 2025 with top-line data anticipated in 2H 2026. XOLREMDI® net revenues for 2024 were $2.6 million, with expectations of increased sales in 2025. Conference call and webcast scheduled for today at 8:30 am ET.

X4 Pharmaceuticals reported financial results for Q4 and full year 2024, highlighting key events and milestones. XOLREMDI® was launched in the U.S. for WHIM syndrome in May 2024, generating $2.6 million in sales by December. Market research shows potential for XOLREMDI in the U.S. and globally for WHIM patients.

Positive results from Phase 2 trial of mavorixafor in chronic neutropenia led to the initiation of a Phase 3 trial in CN. The trial is activated at ~90% of targeted sites worldwide, with full enrollment expected in 3Q or 4Q 2025 and top-line data in 2H 2026. Refinements to the 4WARD protocol have increased confidence in trial outcomes.

X4 Pharmaceuticals announced a strategic restructuring to maximize the opportunity for mavorixafor in chronic neutropenia. The company aims to decrease spending by $30-35 million annually by reducing headcount, discontinuing research efforts, and streamlining spending. Cash position as of December 31, 2024, was $102.8 million.

WHIM syndrome, a rare primary immunodeficiency, is characterized by low blood levels of neutrophils and lymphocytes, leading to frequent infections. XOLREMDI® (mavorixafor) is a once-daily oral treatment approved in the U.S. for WHIM patients. Chronic neutropenia is a rare blood condition with persistent low levels of neutrophils, increasing infection risk.

X4 Pharmaceuticals is focused on developing and commercializing innovative therapies for rare immune system diseases. Mavorixafor is currently marketed in the U.S. as XOLREMDI®, with ongoing clinical trials for additional indications. The company is headquartered in Boston, Massachusetts.



Read more at GlobeNewswire:: X4 Pharmaceuticals Reports Fourth Quarter and Full Year